Table 2.

Logistic Regression Analysis for Variables Predicting an Improved Renal Function (ΔeGFR_5 yr >0) After 5 Years of Follow‐up (n=2284)

	Univariate		Multivariate Model
	OR (95% CI)	P Value	OR (95% CI)	P Value
Age	0.980 (0.972–0.987)	<0.001a	0.980 (0.972–0.989)	<0.001a
Male	0.915 (0.761–1.101)	0.347
Body mass index	1.015 (0.988–1.044)	0.279
CHA2DS2VASc score	0.946 (0.897–0.999)	0.044a
CHF	0.746 (0.505–1.102)	0.141
Hypertension	0.840 (0.712–0.990)	0.037a	1.005 (0.826–1.222)	0.961
Diabetes mellitus	0.888 (0.714–1.105)	0.288
Stroke/TIA	0.914 (0.706–1.183)	0.494
Vascular disease	1.037 (0.822–1.308)	0.759
ACEi/ARB use	0.801 (0.675–0.949)	0.010a	0.871 (0.715–1.060)	0.169
BB use	0.855 (0.714–1.024)	0.089
Statin use	0.985 (0.821–1.181)	0.870
AFCA	2.021 (1.666–2.450)	<0.001a	2.023 (1.666–2.457)	<0.001a

The CHA₂DS₂VASC score was not included in multivariate model in Table 2 because the age and hypertension variables had already been considered to calculate the CHA₂DS₂VASc score. ACEi indicates angiotensin‐converting enzyme inhibitor; AFCA, atrial fibrillation catheter ablation; ARB, angiotensin type II receptor blocker; BB, beta blocker; CHF, congestive heart failure; OR, odds radio; TIA, transient ischemic attack.

^aStatistical significance.